OHDSI MEETINGS THIS WEEK
OHDSI Community Call - Tuesday at 12pm ET
US TOLL: +1-415-655-0001
Meeting Number: 199 982 907
OHDSI Atlas/WebAPI Working Group - Wednesday’s at 10am ET
GIS Working Group Meeting - Next Monday (November 26th) at 10am ET
Meeting Number: 735 317 239
Simple, modern video meetings for the global workforce. Join from anywhere, including your desktop, browser, mobile device, or video room device.
2018 OHDSI Symposium Materials - All slides, handouts and abstracts from this year’s symposium have been uploaded here: https://www.ohdsi.org/past-events/2018-ohdsi-symposium-materials/
2018 OHDSI Symposium Recording - Video records from the main symposium are available here: https://www.ohdsi.org/2018-ohdsi-symposium-videos/
2018 Tutorial Recordings - Tutorial recordings are still under review. We are aiming to have them posted over the next few weeks. Announcements will be made on the forum as they become available.
2019 OHDSI F2F - SAVE THE DATE! The 2019 OHDSI F2F will take place on June 3-4th 2019 at Case Western Reserve University in Cleveland, OH. More details about the theme of the meeting will be posted shortly
I have never been lost, but I will admit to being confused for several weeks.
Daniel Boone COMMUNITY PUBLICATIONS
A Method for Harmonization of Clinical Abbreviation and Acronym Sense Inventories
Development and validation of the PEPPER framework (Prenatal Exposure PubMed ParsER) with applications to food additives
Effect of fenofibrate on uric acid level in patients with gout.
JY Jung, Y Choi, CH Suh, D Yoon and HA Kim,
Scientific reports, Nov 2018 13
Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia. Hypertriglyceridemia is common among patients with gout, and fenofibrate is usually used to reduce triglyceride levels. The aim of this study is to determine the effect of uric acid reduction by fenofibrate in patients with gout administered uric acid lowering agents (viz., the xanthine oxidase inhibitors allopurinol and febuxostat). Data from 863 patients with gout were collected from electronic medical records comprising information on underlying diseases, laboratory findings, and drug histories. Among all the patients, 70 (8.11%) took fenofibrate with allopurinol or febuxostat. Male and young patients took fenofibrate more frequently, and hypertension was less frequent in patients administered xanthine oxidase inhibitors and fenofibrate than in those administered only xanthine oxidase inhibitors. After the treatment, serum uric acid levels more significantly decreased (-1.81 ± 2.41 vs. -2.40 ± 2.28 mg/dL, p = 0.043) in patients with fenofibrate cotreatment, than in those administered allopurinol or febuxostat alone. The effect of uric acid reduction was larger (b = -1.098, p < 0.001) in patients taking glucocorticoids than in those administered other treatments. There was no difference in the levels of creatinine, blood urea nitrogen, and aminotransferases between patients treated with and without fenofibrate. Fenofibrate additionally reduced uric acid levels without showing any change in the results of renal or liver function tests, suggesting that the addition of fenofibrate is a reasonable option for treating gout in patients having high triglyceride levels.
Finding factors that predict treatment-resistant depression: Results of a cohort study.
MS Cepeda, J Reps and P Ryan,
Depression and anxiety, Jul 2018
Treatment for depressive disorders often requires subsequent interventions. Patients who do not respond to antidepressants have treatment-resistant depression (TRD). Predicting who will develop TRD may help healthcare providers make more effective treatment decisions. We sought to identify factors that predict TRD in a real-world setting using claims databases.A retrospective cohort study was conducted in a US claims database of adult subjects with newly diagnosed and treated depression with no mania, dementia, and psychosis. The index date was the date of antidepressant dispensing. The outcome was TRD, defined as having at least three distinct antidepressants or one antidepressant and one antipsychotic within 1 year after the index date. Predictors were age, gender, medical conditions, medications, and procedures 1 year before the index date.Of 230,801 included patients, 10.4% developed TRD within 1 year. TRD patients at baseline were younger; 10.87% were between 18 and 19 years old versus 7.64% in the no-TRD group, risk ratio (RR) = 1.42 (95% confidence interval [CI] 1.37-1.48). TRD patients were more likely to have an anxiety disorder at baseline than non-TRD patients, RR = 1.38 (95% CI 1.35-1.14). At 3.68, fatigue had the highest RR (95% CI 3.18-4.25). TRD patients had substance use disorders, psychiatric conditions, insomnia, and pain more often at baseline than non-TRD patients.Ten percent of subjects newly diagnosed and treated for depression developed TRD within a year. They were younger and suffered more frequently from fatigue, substance use disorders, anxiety, psychiatric conditions, insomnia, and pain than non-TRD patients.
DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial